|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, October 08, 2015 ) GBI Research, a leading business intelligence provider, has released its latest research report: “Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches”. The report provides estimates of the market size for 2013, along with forecasts until 2020 for the Asia-Pacific markets of India, China, Australia and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Ovarian Cancer (OC).
Platinum-based chemotherapy, predominantly the chemotherapy regimen paclitaxel and carboplatin, is the standard of care for the treatment of platinum-sensitive OC (both first-line and recurrent). The initial treatment is quite effective, with the majority of patients entering remission. However, almost all relapse, and after successive periods of remission and relapse either die or progress to platinum-resistant disease, for which the prognosis is poor. There is a clear gap in the market for maintenance therapies, as well as for more effective treatment options in platinum-resistant or refractory patients.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=242400
Although the current developmental pipeline is quite crowded, efficacy with these late-stage drugs has been poor, at best demonstrating minimal improvements in progression-free survival, but not overall survival. The promising investigational drug candidates olaparib and trebananib are expected to gain approval during the forecast period. However, even on approval they are not expected to have a high market penetration, owing to their minimal therapeutic efficacy and anticipated premium prices. As a result, the OC market in APAC is expected not be driven by new drug approvals, but primarily by inflation, and the increase in the prevalence of OC. Market revenue is forecast to rise at a limited CAGR of 5.1% to $417.6m in 2020.
Despite the poor clinical performance of current late-stage pipeline drugs, there is evidence of continued interest in the OC market, with a high number of drug candidates in the initial developmental pipeline, particularly at the Preclinical phase. There is a wide range of novel molecular targets distributed among these drug candidates, including growth factors, serine/threonine protein kinases and tumor associated antigens. This suggests a continued interest in introducing more targeted therapies into the treatment of OC, the use of which in this indication lags significantly behind that in others in oncology.
Browse Detail Report With TOC @ http://www.researchmoz.us/ovarian-cancer-therapeutics-in-asia-pacific-markets-to-2020-off-patent-chemo-regimens-to-retain-dominance-despite-new-launches-report.html
Scope
The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts for OC. It covers and includes:
A brief introduction to OC, including the disease’s pathogenesis, risk factors and diagnosis
In-depth analysis of the drug combinations used in the treatment of OC, including analyses of their safety, efficacy, and place in the disease treatment algorithm, as well as a heat map comparing the drug combinations in terms of safety and efficacy
A comprehensive review of the pipeline for OC therapies, including individual analysis of a number of late-stage pipeline drugs that have the potential to enter the market in the forecast period; the pipeline is analyzed on the basis of phase distribution, molecule type and molecular target, and route of administration
Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, and trial duration, and program failure rate analyses for each molecule type and mechanism of action
Multi-scenario forecast market data to 2020, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and the changes in disease epidemiology across the APAC markets
Discussion of the drivers and barriers for market growth
In-depth analysis of licensing and co-development deals involving drugs indicated in OC, including an outline of the key deals
Browse All Reports in Therapeutic Area Category @ http://www.researchmoz.us/therapeutic-area-market-reports-37.html
Reasons To Buy
The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to:
Understand the efficacy and safety of the current monotherapies and drug combinations used in the treatment of OC, with in-depth analysis of the disease treatment algorithm
Understand the key signaling pathways and molecular targets currently under investigation in OC drug development
Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent
Observe the trends in clinical trial duration and size among clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for OC therapeutics
Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the OC therapeutics market
Table Of Content
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Pathophysiology
2.1.1 Ovarian Cancer – A Group of Distinct Diseases
2.1.2 Ovarian Cancer is Highly Heterogenic with Multiple Mutations and Affected Signaling Pathways
2.2 Symptoms and Diagnosis
2.3 Risk Factors
2.3.1 Age
2.3.2 Inherited Genetic Mutations
2.3.3 Greater Number of Lifetime Ovulations
2.3.4 Weight
2.3.5 Previous Medical Conditions
2.4 Treatment Algorithm
2.4.1 Surgery
2.4.2 First-Line Chemotherapy
2.4.3 Maintenance Therapy
2.5 Recurrent Disease
3 Marketed Products
3.1 Carboplatin
3.2 Paclitaxel
3.3 Gemcitabine
3.4 Topotecan
3.5 Pegylated Liposomal Doxorubicin
3.6 Yondelis
3.7 Avastin
4 Product Pipeline
4.1 Overview of Pipeline by Phase and Route of Administration
4.2 Overview of Pipeline by Molecule Type, Mechanism of Action and Molecular Target
4.2.1 Molecular Targets in the Developmental Pipeline
4.3 Clinical Trials
4.3.1 Clinical Trial Duration
4.3.2 Clinical Trial Size
4.3.3 Failure Rate
4.3.4 Discussion
4.4 Late-Stage Drugs in Developmental Pipeline
4.4.1 Niraparib
4.4.2 Olaparib
4.4.3 Vargatef
4.4.4 Trebananib
4.4.5 Farletuzumab
4.4.6 Karenitecin
4.5 Discussion
5 Market Forecasts
5.1 Asia-Pacific
5.1.1 Overview
5.1.2 Treatment Use Patterns and Revenues in Asia-Pacific Markets
5.2 India
5.2.1 Treatment Use Patterns
5.2.2 Annual Cost of Therapy
5.2.3 Market Forecast
5.3 China
5.3.1 Treatment Use Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Forecast
5.4 Japan
5.4.1 Treatment Use Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Forecast
5.5 Australia
5.5.1 Treatment Use Patterns
5.5.2 Annual Cost of Therapy
5.5.3 Market Forecast
5.6 Drivers and Barriers
5.6.1 Drivers
5.6.2 Barriers
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=enquiry&repid=242400
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Researchmoz Global Pvt.Ltd
Researchmoz
+1-518-621-2074
sales@researchmoz.us
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
